A meta-analysis of 12 case-control studies by Pasche et al. [4] indicates that Tgfbr1-6A carriers have an increased risk of colon, breast, and ovarian cancers compared with non-carriers. This evidence concerns the gene TGFBR1 and ovarian cancer.